Ontology highlight
ABSTRACT:
SUBMITTER: Suzuki H
PROVIDER: S-EPMC3915637 | biostudies-other | 2013 May
REPOSITORIES: biostudies-other
Suzuki Hidekazu H Hirashima Tomonori T Kobayashi Masashi M Okamoto Norio N Matsuura Yuka Y Tamiya Motohiro M Morishita Naoko N Okafuji Kohei K Shiroyama Takayuki T Morimura Osamu O Morita Satomu S Kawase Ichiro I
Molecular and clinical oncology 20130301 3
Interstitial lung diseases (ILDs) are frequently associated with lung cancer. The safety of carboplatin plus paclitaxel in combination with bevacizumab (CP-B) in patients with ILD and lung cancer (ILD-LC) remains to be clarified. In the present study, the safety and efficacy of CP-B treatment in ILD-LC patients were retrospectively investigated. Four patients, who completed CP-B therapy, were included in this study. The dose of carboplatin was the area under the curve 5, paclitaxel was 200 mg/m< ...[more]